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Abstract We have recently shown that the ATP-forming
SUCLA2 subunit of succinyl-CoA ligase, an enzyme of the
citric acid cycle, is exclusively expressed in neurons of the
human cerebral cortex; GFAP- and S100-positive astroglial
cells did not exhibit immunohistoreactivity or in situ hybrid-
ization reactivity for either SUCLA2 or the GTP-forming
SUCLG2. However, Western blotting of post mortem samples
revealed a minor SUCLG2 immunoreactivity. In the present
work we sought to identify the cell type(s) harboring
SUCLG2 in paraformaldehyde-fixed, free-floating surgical
human cortical tissue samples. Specificity of SUCLG2 anti-
serum was supported by co-localization with mitotracker or-
ange staining of paraformaldehyde-fixed human fibroblast
cultures, delineating the mitochondrial network. In human
cortical tissue samples, microglia and oligodendroglia were
identified by antibodies directed against Iba1 andmyelin basic
protein, respectively. Double immunofluorescence for
SUCLG2 and Iba1 or myelin basic protein exhibited no co-
staining; instead, SUCLG2 appeared to outline the cerebral
microvasculature. In accordance to our previous work there
was no co-localization of SUCLA2 immunoreactivity with
either Iba1 or myelin basic protein. We conclude that
SUCLG2 exist only in cells forming the vasculature or its
contents in the human brain. The absence of SUCLA2 and
SUCLG2 in human glia is in compliance with the presence of
alternative pathways occurring in these cells, namely the
GABA shunt and ketone body metabolism which do not
require succinyl CoA ligase activity, and glutamate dehydro-
genase 1, an enzyme exhibiting exquisite sensitivity to inhi-
bition by GTP.
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Introduction
Succinyl CoA ligase (SUCL) is a heterodimeric enzyme,
composed of an invariant α subunit encoded by SUCLG1
and a substrate-specific β subunit, encoded by either
SUCLA2 or SUCLG2. This dimer combination results in
either an ATP-forming (EC 6.2.1.5) or a GTP-forming
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SUCL (EC 6.2.1.4). The enzyme catalyzes the conversion of
succinyl-CoA and ADP (or GDP) to CoASH, succinate and
ATP (or GTP) in the mitochondrial matrix, as part of the citric
acid cycle (Johnson et al. 1998a). ΔG for this reaction is
0.07 kJ/mol and therefore it is reversible (Li et al. 2013).
In frequently used laboratory animals such as rodents,
SUCLA2 and SUCLG2 exhibit quantitative differences in a
tissue-specific expression, as opposed to humans where differ-
ential expression in some tissues appears to be qualitative
(Johnson et al. 1998b; Lambeth et al. 2004). Characteristically,
in the human brain SUCLA2 is found only in the neurons, while
SUCLG2 is not found either in neurons or in glial fibrillary acidic
protein (GFAP)- and S100-positive astroglial cells (Dobolyi et al.
2013).
Mindful of the weak immunoreactivity for SUCLG2 in
Western blotting experiments from post mortem human brain
samples (Dobolyi et al. 2013), we sought to identify the cell
type(s) harboring mitochondria with this protein. In our pre-
vious study, we identified neurons and astrocytes using the
markers Nissl and GFAP/S100, respectively (Dobolyi et al.
2013). In the present work we extended our investigation by
including the microglial marker ionized calcium-binding
adapter molecule 1 (Iba1) and oligodendroglial marker myelin
basic protein.
Materials and methods
Cell cultures Fibroblast culture from skin biopsies from a
control subject was prepared. Cells were grown on poly-L-
ornithine coated 25mm round glass coverslips for 5–7 days, at
a density of approximately 8*105 cells/coverslip in
RPMI1640 medium (GIBCO, Life technologies, Carlsbad,
CA, USA) supplemented with 10 % fetal bovine serum and
2 mM glutamine and kept at 37 °C in 5 % CO2. The medium
was also supplemented with penicillin, streptomycin and
amphotericin (item A5955, Sigma-Aldrich St. Louis, MO,
USA).
Immunocytochemistry of cell cultures Fibroblasts cultures
were first treated with 1 μM Mitotracker Orange (MTO) for
5 min in their culture media, at 37 °C in 5 % CO2. Subsequent
immunocytochemistry of the cultures was performed by fix-
ing the cells with 4 % paraformaldehyde in phosphate-
buffered saline (PBS) for 20 min, followed by perme-
abilization by 0.1 % TX-100 (in PBS) for 10 min and several
washing steps in between with PBS at room temperature.
Cultures were treated with 10 % donkey serum overnight at
4 °C followed by bathing in 1 % donkey serum and
0.175 μg/ml anti-SUCLG2 (Atlas Antibodies AB,
AlbaNova University Center, Stockholm, Sweden, Cat. No.
HPA046705) for 1 h, at room temperature. This antibody was
raised by immunizing rabbits with a recombinant fragment
corresponding to the amino acid region 363–432 of human
SUCLG2 (NP_003839). Therefore, it should not be able to
distinguish among transcript variants (Dobolyi et al. 2013).
Cells were subsequently decorated by using the appropriate
Alexa 488-linked secondary antibody (1:5,000, donkey anti-
rabb i t , Jackson Immunochemica l s Europe Ltd ,
Cambridgeshire, UK) in the presence of 1 % donkey serum.
Human brains Human brain samples were collected in accor-
dance with the Ethical Rules for Using Human Tissues for
Medical Research in Hungary (HM 34/1999) and the Code of
Ethics of the World Medical Association (Declaration of
Helsinki). Surgical brain samples were obtained from tissue
removed during brain surgeries at the National Institute of
Clinical Neurosciences, Budapest, Hungary in the framework
of the Human Brain Tissue Bank and Laboratory,
Semmelweis University, Budapest. Prior written informed
consent was obtained from the patients that included the
request to conduct neurochemical analyses. The protocols
including analyses of tissue samples were approved by insti-
tutional ethics committee of the Semmelweis University. The
surgical patients underwent the removal of brain tumors. The
medical history of the subjects was obtained from medical or
hospital records, interviews with family members and rela-
tives, as well as from pathological and neuropathological
reports. All personal identifiers had been removed and sam-
ples were coded before the analyses of tissue. Immunolabeling
was performed using frontal cortical sample of a 58 years old
man and temporal cortical samples from 64 to 66 years old
women.
Tissue collection for immunolabeling For immunocytochem-
istry, brains were cut into 5–10 mm thick coronal slices and
immersion fixed in 4 % paraformaldehyde in 0.1 M PBS for
3–5 days. Subsequently, the blocks were transferred to PBS
containing 0.1 % sodium azide for 2 days to remove excess
paraformaldehyde. Then the blocks were placed in PBS con-
taining 20% sucrose for 2 days for cryoprotection, after which
the blocks were frozen and cut into 50 μm thick serial coronal
sections on a sliding microtome. Sections were collected in
PBS containing 0.1 % sodium azide and stored at 4 °C until
further processing.
Double labeling of SUCLA2 and SUCLG2 with glial markers
in brains sections Every fifth free-floating brain section of
human temporal and frontal cortical blocks was immuno-
stained for SUCLA2, SUCLG2, and for glial markers. First,
the glial markers were applied. Oligodendrocytes were labeled
with a mouse anti-myelin basic protein antibody (1:100,
Abcam, Cambridge, UK; cat. number: ab24567) while mi-
croglia were stained with goat anti-Iba1 (1:500, Abcam; cat.
number: ab107159). Thus, the sections were incubated in the
primary antibodies for 24 h at room temperature, then in Alexa
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594 donkey anti-mouse or anti-goat secondary antibodies
(1:500; Molecular Probes, Eugene, OR) for 2 h and washed.
Subsequently, rabbit anti-SUCLA2 (Proteintech Europe
Ltd, Manchester, UK, Cat. No. # 12627-1-AP) and anti-
SUCLG2 antisera were applied using 1:1,000 dilution
followed by incubation of the sections in biotinylated
anti-rabbit secondary antibody (1:1,000 dilution; Vector
Laboratories, Burlingame, CA) and then in avidin-
biotin-peroxidase complex (1:500; Vector Laboratories)
for 2 h. Subsequently, the labeling was visualized by
incubation in fluorescein isothiocyanate (FITC)-tyramide
(1:8,000) and H2O2 in 100 mM Trizma buffer (pH 8.0
adjusted with HCl) for 6 min. Finally, all sections were
mounted on positively charged slides (Superfrost Plus,
Fisher Scientific, Pittsburgh, PA) and coverslipped in
antifade medium (Prolong Antifade Kit, Molecular
Probes).
Image processing Fluorescent sections were evaluated using
a Bio-Rad 2100 Rainbow Confocal System (Bio-Rad
Laboratories, Inc, CA, USA). For the human brain specimens,
pictures were taken at the frequencies of the two dyes and also
in the far red range. This latter imagewas subtracted from both
of the other two images in order to cancel-out significant
autofluorescence of the sections which was detected in all
channels. Subsequently, the contrast and sharpness of the
images were adjusted using the “levels” and “sharpness”
commands in Adobe Photoshop CS 8.0. Full resolution was
maintained until the photomicrographs were finally cropped at
which point the images were adjusted to a resolution of
300 dpi.
Results
The specificity of SUCLG2 immunoreactivity in human
fibroblast cultures
We have used a new antibody directed against the human
SUCLG2 protein that does not distinguish among various
isoforms (see “Materials and Methods”) as in (Dobolyi et al.
2013). The specificity of SUCLG2 immunoreactivity was
validated using human fibroblast cells, see Fig. 1. The mito-
chondrial network was selectively stained by loading cells
with Mitotracker Orange (MTO, 1 μM) prior to fixation
(panel a). Fibroblasts were subsequently labeled with the
procedure of SUCLG2 immunostaining (panel b), and there
was a co-localization with the decoration obtained by MTO
(panel c). Note that only a minority of the mitochondrial
network was stained by the SUCLG2 antiserum, as opposed
to SUCLA2 immunoreactivity in the same cells, in which the
majority of the mitochondrial network was stained (Dobolyi
et al. 2013).
Fig. 1 Co-labeling of human fibroblasts (SUCLG2) with Mitotracker
Orange (MTO). aMTO labeling outlining the mitochondrial network in
normal human fibroblasts. b SUCLG2 immunoreactivity in normal hu-
man fibroblasts. Intracellular structures resembling mitochondria are
intensely labeled c Merged image of SUCLG2 immunodecoration with
MTO labeling. Scale bar=13 μm
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SUCLA2 and SUCLG2 labeling in the cerebral cortex
SUCLA2 immunoreactivity appeared in cells located through-
out the cerebral cortex (Fig. 2a). The cellular distribution of
SUCLA2 labeling suggested that SUCLA2 immunoreactivity
is restricted to mitochondria (see Fig. 3a), exactly as described
by us previously (Dobolyi et al. 2013). Furthermore, the
distribution of SUCLA2-immunoreactive cells corresponded
to that of neurons in accordance with the previously described
neuronal expression of this protein. In these sections, the walls
of large blood vessels were also labeled with SUCLA2, see
upper left corner of figure panel 2a. The distribution of
SUCLA2 immunoreactivity differed markedly from that of
myelin basic protein as the latter one was striking in the white
matter and labeled radially arranged structures in accordance
with the established localization of myelinated fibers within
the cortex (Fig. 2b). Indeed, double labeling confirmed the
absence of co-localization between SUCLA2 and myelin ba-
sic protein (Figs. 2c, 3b). The distribution of Iba1-labeled
microglial cells was relatively even within the examined brain
section corresponding to the role of this cell type in immune
defense (Fig. 2e). Microglial cells had small somata and
several processes (Fig. 3a). Thus, the morphology of
SUCLA2 and Iba1-labeled cells was different. Consistent with
this, no co-localization of these markers were found in any
cortical regions examined (Fig. 3a).
Fig. 2 Immunocytochemical
identification of succinyl CoA
ligase subunits, oligodendroglia,
and microglia in the human
cerebral cortex. The distribution
of SUCLA2 (a), myelin basic
protein (b), SUCLG2 (d) and Iba1
(e) immunoreactivities are shown
in low magnification. c Double
labeling (panels a and b
combined) show somewhat
overlapping but still
fundamentally different
distributions of SUCLA2 and
myelin basic protein. f Double
labeling (panels d and e
combined) demonstrate the
distinct distributions of SUCLG2
and Iba1 in the cerebral cortex.
Scale bar=500 μm
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SUCLG2 immunoreactivity was found in all layers of the
human cerebral cortex. Its distribution was, however, charac-
teristic of blood vessels suggesting endothelial and/or
pericytic localization. However, we must note that
perivascular staining due to the presence of SUCLG2 in
astrocyte end-feet is a viable possibility. The distribution of
SUCLG2 immunoreactivity was clearly different from that of
myelin basic protein (Fig. 2b) and Iba1-positive microglia
(Fig. 2e), which was also confirmed by double labeling
(Fig. 2f). Analysis of high magnification images revealed that
SUCLG2 immunoreactivity present in structures resembling
mitochondria appeared in capillary-forming cells. This is best
depicted in the lower left corner (two white arrowheads) and
upper right corner (single white arrowhead) of figure panel 3d;
note the SUCLG2 decoration pattern forming a tubular struc-
ture around the red blood cells (stained green because of the
immunohistochemical procedure, detailed in “Materials and
Methods”) in a longitudinal (lower left corner) and cross-
section (upper right corner) mode delineating a capillary. No
co-localization was found between SUCLG2 and the microg-
lia marker Iba1 (Fig. 3c) and oligodendroglial marker myelin
basic protein (Fig. 3d). On the other hand, SUCLG2 expres-
sion has been demonstrated in microglial cells of post-mortem
brains of Alzheimer’s disease patients and age-matched con-
trols (Ramirez et al. 2014).
In humans, SUCLG2 exhibits transcript variants. However,
the possibility that the human glial transcript variant of
SUCLG2 is not recognized by existing antibodies has been
ruled out in (Dobolyi et al. 2013): all transcripts are identical
in the region 1–396, except in position 220 (Dobolyi et al.
2013). The antibody used in (Dobolyi et al. 2013) to identify
SUCLG2 was raised by immunizing rabbits with a recombi-
nant fragment corresponding to a region within the N terminal
amino acids 1–204 of human SUCLG2 which is common
among all transcript variants. Furthermore, in (Dobolyi et al.
2013), PCR and in situ hybridization for all known variants
have been performed for human brain material; SUCLG2
mRNA was deduced to be very scarce in the human brain,
while the same probes tested robustly positive in human
fibroblasts.
Discussion
The present article is a follow-up on the lead provided by our
previous work showing that SUCLG2 is very weakly
expressed in the human brain, and it is not found in either
neurons or astrocytes (Dobolyi et al. 2013). Here, the most
important finding is that SUCLG2 expression was further
confirmed to be absent from microglia and oligodendroglia,
but it was detected in cells forming the microvasculature, most
likely endothelial cells and/or pericytes.
Fig. 3 High magnification
confocal images demonstrate that
SUCLA2 immunoreactivity
(green in a and b) is present in
neurons but not in Iba1-positive
microglia cells (red in a) and in
oligodendroglial cells labelled
with basic myelin protein (red in
b). In turn, SUCLG2
immunoreactivity (green in c and
d) does not co-localize with Iba1
(redmicroglia cells in c) and cells
labelled with basic myelin protein
(red oligodendroglial cells in d).
The arrowheads in d point to red
blood cells within vessels labelled
non-specifically due to their
internal peroxidase content. Scale
bar=20 μm
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An additional finding is that SUCLG2 staining in human
fibroblasts covered only a small fraction of the mitochondrial
network. On the other hand, SUCLA2 staining covered the
majority of mitochondria in the same cells (Dobolyi et al.
2013). It would be interesting to see a triple-colocalization study
of SUCLG2, SUCLA2 andmitotracker orange in the same cell; a
non-overlapping SUCLA2-SUCLG2 staining would signify the
presence of two different mitochondrial populations regarding
succinyl CoA ligase activity, one representing the ATP-forming
population, and the other the GTP-forming tier. This would not
be too surprising; ATP is associated with catabolic pathways,
while GTP with anabolism (Pall 1985). GTP is very valuable in
the mitochondrial matrix, as it cannot be transported through the
inner mitochondrial membrane of higher organisms (Pfaff et al.
1965), hence it also regenerated through salvage reactions.
Currently, such a co-staining is not possible or at least technically
very challenging because both available antibodies directed
against SUCLA2 and SUCLG2 are raised in rabbits. We are in
the process of generating a SUCLG2 antibody raised in goats
directed against the same epitope as the present anti-rabbit anti-
body, for the purpose of simultaneous SUCLA2 and SUCLG2
co-staining.
The characterization of cell-specific SUCLA2 and
SUCLG2 expression is significant because the simultaneous
absence of both proteins in any cell imply a missing step in the
citric acid cycle as we know it. Apparently, this seems to be
the case for astrocytes, microglia, and oligodendrocytes in the
human brain. The question arises, how can these cells perform
normal metabolic functions, in the absence of an intact citric
acid cycle?
To address this, we must first elaborate on the relevant bio-
chemical pathways. As it is mentioned in the “Introduction”,
succinyl CoA ligase is a reversible enzyme; when it proceeds
towards generation of succinyl-CoA, this product may only
follow heme- or ketone body metabolism (Labbe et al. 1965;
Ottaway et al. 1981; Dringen et al. 2007; Lopes-Cardozo et al.
1986) because it cannot be processed further by the irreversible
α-ketoglutarate dehydrogenase complex (Chinopoulos 2013).
When succinyl CoA ligase operates in the opposite direction
towards ATP or GTP formation (a process termed ‘substrate-
level phosphorylation’), it yields succinate that can be either
further processed by succinate dehydrogenase, and advance in
the citric acid cycle, or act as a metabolic signal in inflammation
(Mills and O’Neill 2014).
In the human brain, there are at least two biochemical
pathways that can mediate a by-pass of succinyl CoA ligase:
i) the ‘GABA shunt’, and ii) ketone metabolism.
The ‘GABA shunt’ (Fig. 4) is a pathway commencing from
glutamate (which could arise from α-ketoglutarate through
glutamate dehydrogenase) being converted to GABA by the
cytosolic glutamate decarboxylase (4.1.1.15), encoded by ei-
ther GAD65 or GAD67 (Soghomonian and Martin 1998).
GABA may also arise by metabolism of putrescine
(Sequerra et al. 2007; Jakoby and Fredericks 1959; De
Mello et al. 1976; Seiler et al. 1973), or enter the cytoplasm
from the extracellular space through transporters in the plasma
membrane. GABA transaminates with α-ketoglutarate to
form glutamate and succinate semialdehyde by the mitochon-
drial GABA transaminase (GABA-T, EC 2.6.1.19). Succinate
semialdehyde will get dehydrogenated by the NAD+-depen-
dent succinate semialdehyde dehydrogenase (EC 1.2.1.24),
encoded by aldehyde dehydrogenase 5 family, member A1
(ALDH5A1) to yield succinate, and thus enter the citric acid
cycle. Succinate semialdehyde can also be converted to
gamma-hydroxybutyrate by succinic semialdehyde reductase,
encoded by AKR7A2 (Picklo et al. 2001), an enzyme that is
primarily localized to astrocytes and microglia of the human
cerebral cortex, hippocampus and midbrain (Picklo et al.
2001; Ris and von Wartburg 1973; Hoffman et al. 1980).
The enzymes required for a complete ‘GABA shunt’ are
present in glial cells in the adult human brain; astrocytes express
glutamate dehydrogenase (both isoforms 1 and 2, see below)
(Spanaki et al. 2014), GAD67 (but not GAD65), GABA-T as
well as the GABAA and GABAB receptors (Lee et al. 2011a;
Schwab et al. 2013) reviewed in (Velez-Fort et al. 2012). The
intensity of immunostaining for GAD67 and GABA-T in these
cells is comparable or greater to that observed for known inhib-
itory neurons. The GABA transporter GAT-3 is exclusively
expressed in astrocytes (Minelli et al. 1996); GAT-1 and -2 are
found in astrocytic processes and other neuronal- and non-
neuronal elements (Conti et al. 1998, 1999). As a result of the
concerted action of these enzymes and transporters, cultured
human astrocytes maintain an intracellular GABA level of
2.32 mM (Lee et al. 2011b). On the same line, cultured human
microglia express the mRNA and protein for GABA-T, in
Fig. 4 Illustration of the pathways bypassing succinyl CoA ligase in
human glia. KGDHC ketoglutarate dehydrogenase complex, GLUD glu-
tamate dehydrogenase, GAD glutamate decarboxylase, GABA γ-
aminobutyric acid, EC space extracellular space, GABA-T GABA trans-
aminase, SSA succinate semialdehyde, SSADH succinate semialdehyde
dehydrogenase, SSAR succinate semialdehyde reductase, GHB γ-
hydroxybutyric acid, SDH succinate dehydrogenase, OXCT1 succinyl-
CoA:3-ketoacid-coenzyme A transferase 1
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addition to GABAA and GABAB receptors (Lee et al. 2011a).
The NAD+-dependent succinate semialdehyde dehydrogenase
encoded by ALDH5A1 is expressed in both neurons and glial
cells in the adult human brain (http://www.proteinatlas.org/
ENSG00000112294/tissue).
Regarding ketone bodies metabolism, it is well established
that 3-hydroxybutyrate and acetoacetate can replace glucose as
the major source of brain energy in situations such as starvation
(Robinson and Williamson 1980). Ketone bodies are not only a
product of the liver, but also of astrocytes: astrocytes produce
ketone bodies from fatty acids (Auestad et al. 1991), and the
branched-chain amino acids valine, isoleucine and leucine
(Murin et al. 2009a, b; Bixel and Hamprecht 1995). A critical
enzyme in ketone body metabolism is the mitochondrial succi-
nyl-CoA:3-ketoacid-coenzyme A transferase 1 (EC 2.8.3.5)
(Hersh and Jencks 1967), encoded by OXCT1. This enzyme
catalyzes the reversible transfer of CoA from succinyl CoA to
acetoacetate yielding acetoacetyl CoA and succinate (Fig. 4).
OXCT1 is expressed in both neurons and glial cells in the human
brain (http://www.proteinatlas.org/ENSG00000083720/tissue).
From the reaction catalyzed by succinyl-CoA:3-ketoacid-
coenzyme A transferase 1, it is apparent that there can be
interconversion of succinate to succinyl CoA and vice versa,
obviating the need for succinyl CoA ligase.
From the above, it is evident that human glia can accom-
modate for the lack of succinyl CoA ligase with the ‘GABA
shunt’ and/or ketone metabolism, and thus maintain produc-
tion of reducing equivalents by the citric acid cycle. However,
it would be erroneous to consider that the ‘GABA shunt’ and
ketone bodies metabolic pathways evolved in these cells in
response to the lack of succinyl CoA ligase. Glia benefit from
shuttling succinyl CoA towards GABA formation and ketone
body metabolism: i) GABA is an effective immunomodula-
tory molecule (Jin et al. 2013); in human astrocytes and
microglia, GABA suppresses the reactive response of the
inflammatory stimulants lipopolysaccharide and interferon-γ
by inhibiting the induction of inflammatory pathways medi-
ated by NFκB and P38 MAP kinase (Lee et al. 2011a); ii)
Ketone bodies produced by the astrocytes may promote neu-
roprotection by supplying them to the neurons (Guzman and
Blazquez 2001).
Alternatively, in the absence of succinyl-CoA ligase, succinyl-
CoA emerging from theα-ketoglutarate dehydrogenase complex
in glial mitochondria could serve as cofactor for lysine
succinylation, a wide-spread post-translational modification
(Zhang et al. 2011), or advance towards porphyrin synthesis.
Furthermore, the absence of a GTP-forming succinyl CoA
ligase (and likewise, of an ATP-forming succinyl CoA ligase,
since ATP can transphosphorylate to GTP by the concerted
action of SUCL with a mitochondrial isoform of a nucleotide
diphosphate kinase known as nm23-H4 (Kadrmas et al. 1991;
Kowluru et al. 2002)) is compatible with the high level of
expression of glutamate dehydrogenase (GLUD) in human
glia (Plaitakis and Zaganas 2001): In the human brain, GLUD
is encoded by either GLUD1 or GLUD2 (Plaitakis and
Zaganas 2001). GLUD1 is potently inhibited by GTP
(IC50=0.20 μM), (Plaitakis and Zaganas 2001). GLUD2 is
refractory to GTP, but it is strongly activated by ADP and
leucine (Spanaki et al. 2012). However, GLUD2 expression is
much lower than GLUD1 (Zaganas et al. 2012). Both GLUD
isoforms are mostly expressed in the astrocytes; oligoden-
droglia or myelinated fibers do not express GLUD2
(Spanaki et al. 2010). To the best of out knowledge, there
are no published data on GLUD2 expression in microglia.
Although the above considerations in conjunction with our
results point to the direction of a truncated citric acid cycle in
human glia, experimental evidence that support or refute this
concept in glia within the adult human brain are as of yet,
lacking; substrate-specific metabolism of in situ astrocytic
mitochondria deduced by isotopomeric analysis of 13C dis-
tributed among various metabolites has been extensively ad-
dressed but only in cell-specific cultures from rodent brain
originating from fetal materials that mature on entirely artifi-
cial conditions (Westergaard et al. 1994; Schousboe et al.
1997; Hassel 2000; McKenna and Sonnewald 2005).
Therefore, extrapolations from such experiments on what
could be actually happening in glia within the adult human
brain -as suggested in Fig. 4—must be exercised with caution.
A potential ‘downside’ for glial cells lacking the capacity for
nucleotide-forming SUCL (substrate-level phosphorylation) is
that their mitochondria are likely to engage in cytosolic ATP
consumption (Chinopoulos et al. 2010; Kiss et al. 2013, 2014;
Chinopoulos 2011a), during natural fluctuations of their mem-
brane potentials (Gerencser et al. 2012) should they become
sufficiently depolarized. By the same token, glial mitochondria
should also be vulnerable in terms of relying on -in house- ATP
reserves during energy crisis, such as during brain ischemia
(Chinopoulos 2011b; Chinopoulos and Adam-Vizi 2010).
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